NCT01042392

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 506 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Aliskiren	150 mg Aliskiren as film-coated tablet
DRUG	Ramipril	Ramipril 5 mg was given in capsule form.
DRUG	Matching placebo to Aliskiren	The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
DRUG	Matching placebo to Ramipril	The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2010-01-05
• Last updated: 2012-04-03
• Results posted: 2012-04-03

Locations

98 sites across 1 country: France